4.1 Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials

Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials

Optimizing antimicrobial pharmacotherapy requires integrating two distinct disciplines: pharmacokinetics (PK), which characterizes the time course of drug absorption, distribution, metabolism, and excretion (what the host does to the drug), and pharmacodynamics (PD), which describes the relationship between drug concentrations and antimicrobial activity or host toxicity (what the drug does to the pathogen and host). The minimum inhibitory concentration (MIC) is an essential, static in vitro threshold; however, it fails to account for dynamic fluctuations in drug exposure in vivo. Integrating PK and PD indices provides the mechanistic foundation for clinical dosing design, therapeutic drug monitoring, and resistance suppression.

---

Antimicrobial PK/PD Indices and Bactericidal Profiling

Antimicrobial agents are classified into three primary PK/PD patterns based on the pharmacodynamic parameter that best correlates with microbiological eradication and clinical cure:

                    Peak Concentration (Cmax)
                             ▲
                             │       Time above MIC (T > MIC)
      Concentration          │     ◄─────────────────────────►
                             │
                             │   █████████████████████
                             │  ██                   ██
                             │ ██                     ██   Area Under the Curve
                             │██                       ██       (AUC24)
                             ██                         ██
  ──────────────────────────██───────────────────────────██────────────── MIC
                           ██                             ██
                          ██                               ██
                         ██                                 ██
  ──────────────────────────────────────────────────────────────────────► Time

---

Time-Dependent Killing and Beta-Lactam Infusion Strategies

Beta-lactam antibiotics exert bactericidal activity by covalently binding penicillin-binding proteins (PBPs), inhibiting the transpeptidation reaction necessary for peptidoglycan cross-linking. Once free drug concentrations exceed 4 to 5 times the MIC, the rate of bacterial killing reaches a maximum plateau; higher peak concentrations do not accelerate bacterial death. Consequently, therapeutic success depends entirely on the fraction of the dosing interval that free (unbound) drug concentrations remain above the MIC (fT > MIC).

Class-Specific Pharmacodynamic Thresholds

• Carbapenems (Meropenem, Imipenem, Doripenem): Require the lowest target (40–50% fT > MIC) due to rapid bactericidal action and a modest post-antibiotic effect (1–2 hours) against Gram-negative bacilli.
• Penicillins (Ampicillin, Piperacillin): Require intermediate targets (50–60% fT > MIC) because they dissociate more rapidly from target PBPs and exhibit negligible post-antibiotic effect against Gram-negative rods.
• Cephalosporins (Cefazolin, Cefuroxime, Ceftriaxone, Cefepime): Require the highest targets (60–70% fT > MIC) due to slower bactericidal kill kinetics and absent post-antibiotic effect against Gram-negative bacilli.

Optimization via Extended and Continuous Infusions

Standard intermittent infusions (administered over 30 minutes) generate high peak concentrations followed by rapid renal elimination, causing drug concentrations to drop below the MIC well before the next scheduled dose—particularly in pathogens with elevated MICs (e.g., Pseudomonas aeruginosa MIC 4–8 mg/L) or in hypermetabolic septic patients. Extending the infusion duration preserves concentrations above the MIC for a substantially greater proportion of the dosing interval without requiring higher daily dosages:

1. Extended Infusions (EI): Infusing the intermittent dose over 3 to 4 hours rather than 30 minutes. Prominent clinical regimens include:
   • Piperacillin-Tazobactam: 3.375 g or 4.5 g IV every 8 hours infused over 4 hours (instead of every 6 hours over 30 minutes).
   • Cefepime: 2 g IV every 8 hours infused over 3 to 4 hours (instead of 30 minutes).
   • Meropenem: 1 g or 2 g IV every 8 hours infused over 3 hours (instead of 30 minutes).
2. Continuous Infusions (CI): Administering the total daily dose as an uninterrupted 24-hour infusion following an initial intravenous loading dose (administered over 30 minutes) to rapidly establish steady-state therapeutic concentrations.
   • Regimens include piperacillin-tazobactam 13.5 g to 18 g IV daily over 24 hours, cefepime 4 g to 6 g IV daily over 24 hours, or meropenem 3 g to 6 g IV daily over 24 hours.

Clinical Evidence and Trial Data

Large-scale clinical trials (including the DALI study, BLING II/III, and the BETA-LACTAM trial) demonstrate that prolonged and continuous beta-lactam infusions significantly increase target attainment (100% fT > MIC), shorten mechanical ventilation duration, and improve clinical cure and 30-day survival in critically ill patients with septic shock, acute respiratory distress syndrome, or multidrug-resistant pathogens.

---

Concentration-Dependent Killing and High-Dose Extended-Interval Aminoglycosides

Aminoglycosides (gentamicin, tobramycin, amikacin) bind irreversibly to the 30S ribosomal subunit, causing codon misreading, mistranslated membrane proteins, and rapid bacterial outer membrane disruption. Their rate and extent of bacterial killing increase proportionally with peak concentration (Cmax).

Conventional Dosing (1.5-2 mg/kg q8h)        High-Dose Extended-Interval (5-7 mg/kg q24h)
Concentration                                Concentration
     ▲                                            ▲   Cmax = 16-24 mcg/mL
     │                                            │   (Cmax / MIC = 8-12x)
     │                                            │  ██
     │  ██        ██        ██                    │ ████
     │ ████      ████      ████                   │██  ██
 2.0 ┼───────┼─────────┼─────────┼─ MIC      2.0 ┼─────────┼───────────────────────── MIC
 1.0 ┼───────────────────────────┼─ Trough    1.0 ┼─────────────────────────────────────
     │   ▲         ▲         ▲                    │           ▲ Undetectable Trough (<0.5)
     └───┴─────────┴─────────┴───► Time           └───────────┴─────────────────────► Time
     Continuous accumulation in cortex!            Complete cortical washout period!

The Mechanism of Adaptive Resistance and Saturable Toxicity

• Adaptive Resistance: Exposure of Gram-negative bacilli to low, sub-lethal aminoglycoside concentrations triggers transient downregulation of active, energy-dependent uptake channels across the bacterial cytoplasmic membrane within 2 to 6 hours. Administering frequent, divided doses (e.g., every 8 hours) maintains continuous low-level exposure, perpetuating this refractory state.
• Saturable Renal Cortical Uptake: Aminoglycoside nephrotoxicity occurs when filtered drug is reabsorbed into renal proximal tubular epithelial cells via endocytic megalin/cubilin receptor complexes, accumulating inside lysosomes and inducing necrosis. Megalin-mediated endocytosis is a saturable process; at high serum concentrations, the uptake receptors become completely saturated. Consequently, a single large peak does not increase renal cortical uptake, whereas frequent divided doses maintain concentrations within the active uptake range continuously.

High-Dose Extended-Interval Dosing (HD-EID) Protocol

• Dosing Strategy: Gentamicin or tobramycin at 5 to 7 mg/kg (amikacin 15 to 20 mg/kg) administered intravenously once every 24 hours (or extended to every 36 or 48 hours based on renal function).
• Pharmacodynamic Advantage: Rapidly achieves a Cmax / MIC ratio of 8 to 10 (e.g., peak of 16–20 mcg/mL for a pathogen MIC of 2 mg/L), optimizing bactericidal action while providing a prolonged drug-free period (<0.5–1 mcg/mL for gentamicin/tobramycin; <2.5–5 mcg/mL for amikacin) that allows intracellular tubular clearance and reverses adaptive resistance.
• Monitoring via Nomograms: Serum concentrations are drawn between 6 and 14 hours post-infusion and plotted onto the Hartford Nomogram (or Urban-Craig / Barnes-Jewish nomograms) to objectively determine the dosing interval (every 24, 36, or 48 hours).

---

Exposure-Dependent Killing: Vancomycin, Fluoroquinolones, and Daptomycin

Vancomycin AUC/MIC Optimization

Vancomycin binds terminal D-alanyl-D-alanine pentapeptides, blocking transglycosylase and transpeptidase steps in peptidoglycan synthesis. Historical practice relied on monitoring steady-state trough concentrations (15–20 mcg/mL for severe MRSA infections). However, extensive clinical data confirmed that trough concentrations are an inaccurate surrogate for total exposure and correlate strongly with acute kidney injury (AKI).

Per the updated 2020 Consensus Guidelines (ASHP/IDSA/PIDS/SIDP):

• Efficacy Target: A 24-hour area under the curve to MIC ratio (AUC24 / MIC) of 400 to 600 mg*h/L, assuming a broth microdilution (BMD) MIC of ≤ 1 mg/L.
• Safety Ceiling: The upper limit of 600 mgh/L must not be exceeded; AUC values >600 mgh/L increase nephrotoxicity 3- to 4-fold without improving clinical efficacy.
• Monitoring Modalities:
  1. Bayesian Dose-Optimization Software (Preferred): Employs population PK models to forecast individual patient kinetics using a single trough or a peak-and-trough pair, permitting real-time adaptive dosing.
  2. First-Order Analytic Equations (Alternative): Involves drawing two post-distribution concentrations during the same dosing interval (peak drawn 1–2 hours post-infusion; trough drawn within 30 minutes before next dose) to calculate the patient's elimination rate constant (ke) and volume of distribution (Vd):

ke = ln(Cpeak / Ctrough) / delta_t
AUC_inf = ((Cpeak + Ctrough) / 2) * t_inf + (Cpeak - Ctrough) / ke
AUC24 = AUC_inf * (24 / tau)

Fluoroquinolones

Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. Their bactericidal activity is exposure-dependent:

• Gram-Negative Bacilli Target: fAUC24 / MIC ≥ 125 is required for Pseudomonas aeruginosa and Enterobacterales to achieve clinical cure and suppress the emergence of resistant topoisomerase mutants within the Mutant Selection Window (MSW).
• Gram-Positive Target: fAUC24 / MIC ≥ 30–50 is sufficient for Streptococcus pneumoniae in community-acquired pneumonia.

Daptomycin and Polymyxins

• Daptomycin: Lipopeptide that inserts into bacterial cytoplasmic membranes in a calcium-dependent manner, creating transmembrane ion-conducting channels that trigger rapid depolarization, potassium efflux, and cell death. The clinical target is an AUC24 / MIC of 666 to 1000 mg*h/L, achieved with weight-based doses of 8 to 10 mg/kg/day (or higher) in deep-seated MRSA and enterococcal bacteremia or endocarditis to prevent emergence of mprF mutations.
• Polymyxins (Colistin and Polymyxin B): Disrupt outer membrane lipopolysaccharide in Gram-negative organisms. Target an average steady-state concentration (Css,avg) of 2 mg/L, corresponding to an AUC24 of 50 to 100 mg*h/L. Polymyxin B is pharmacokinetically preferred over colistimethate sodium (CMS) for systemic infections because it is administered as active drug, does not rely on variable renal prodrug conversion, and carries a significantly lower rate of nephrotoxicity.

---

Post-Antibiotic Effect (PAE) and Sub-MIC Dynamics

The Post-Antibiotic Effect (PAE) represents the persistent suppression of bacterial growth following brief exposure to an antimicrobial, after drug concentrations fall below the organism's MIC. The duration of PAE is quantified as:

PAE = T - C

(where T is the time required for the viable bacterial count to increase by 1 log10 CFU/mL following antimicrobial removal, and C is the corresponding time for an untreated control culture).

---

Compartmental Distribution and Tissue Penetration

Clinical success requires achieving therapeutic antimicrobial concentrations at the actual site of infection. Free, non-protein-bound drug (fu) is the only fraction capable of crossing biological membranes and exerting microbiological activity.

┌────────────────────────────────────────────────────────┐
│                     Blood Plasma                       │
│     [Bound Drug ◄──► Free Drug (fu)]                   │
└──────────────────────────┬─────────────────────────────┘
                           │ Passive Diffusion / Transporters
       ┌───────────────────┼───────────────────┐
       ▼                   ▼                   ▼
┌──────────────┐   ┌──────────────┐   ┌──────────────────┐
│  CNS / CSF   │   │Pulmonary ELF │   │   Urinary Tract  │
│ BBB tight    │   │Alveolar cell │   │ Glomerular filt. │
│ junctions;   │   │uptake; high  │   │ vs tubular sec.; │
│ inflammation │   │for macrolide/│   │ high in urine:   │
│ opens pores  │   │FQ; surfactant│   │ cipro/levo;      │
│              │   │inactivates   │   │ zero in urine:   │
│              │   │daptomycin!   │   │ moxifloxacin!    │
└──────────────┘   └──────────────┘   └──────────────────┘

Central Nervous System (CNS) and Cerebrospinal Fluid (CSF)

Penetration through the blood-brain barrier (BBB) is governed by lipophilicity, low molecular weight (<400–500 Da), low plasma protein binding, and absence of P-glycoprotein efflux transport:

• Meningeal Inflammation: In the uninflamed state, endothelial paracellular tight junctions severely restrict hydrophilic beta-lactams and glycopeptides (CSF:serum ratios <5%). During acute bacterial meningitis, inflammatory cytokines loosen tight junctions, increasing CSF penetration of ceftriaxone (10–15%), ampicillin (10–15%), meropenem (10–20%), and vancomycin (5–15%).
• Impact of Dexamethasone: Adjunctive dexamethasone (administered before or with the first dose of antibiotics in suspected pneumococcal meningitis) reduces subarachnoid inflammation and may decrease vancomycin CSF penetration; thus, high-dose regimens (e.g., ceftriaxone 2 g IV q12h + vancomycin 15–20 mg/kg IV q8–12h with or without rifampin) must be maintained.
• Inadequate CSF Agents: Echinocandins, aminoglycosides, first- and second-generation cephalosporins, and macrolides do not cross the blood-brain barrier and must never be used for CNS infections.

Pulmonary Epithelial Lining Fluid (ELF)

• High Penetration: Lipophilic and basic agents concentrate extensively in alveolar macrophages and pulmonary epithelial lining fluid: Macrolides (azithromycin ELF:plasma >10–50), Linezolid (ELF:plasma ~1–1.2), and Fluoroquinolones (levofloxacin, moxifloxacin ELF:plasma >2–3).
• Moderate Penetration: Beta-lactams achieve moderate penetration into ELF (ELF:plasma ratios 20–50%), necessitating maximal dosing (e.g., cefepime 2 g IV q8h extended infusion, meropenem 2 g IV q8h extended infusion) to clear nosocomial pneumonia.
• Pulmonary Surfactant Inactivation of Daptomycin: Daptomycin relies on calcium to form active membrane-disrupting oligomers. Pulmonary surfactant is rich in dipalmitoylphosphatidylcholine (DPPC), which sequesters and binds daptomycin, neutralizing its antibacterial activity. Daptomycin is strictly contraindicated in pneumonia and alveolar pulmonary infections.

Bone and Synovial Fluid

• Osteomyelitis and Hardware: Penetration is impeded by bone mineral matrix, ischemia, and biofilm. High-bioavailability oral agents with superior osseous penetration include fluoroquinolones, clindamycin, and linezolid. Rifampin achieves high penetration into staphylococcal hardware biofilms but must always be paired with a companion agent (e.g., cefazolin, vancomycin, or ciprofloxacin) to prevent rapid rpoB point mutation resistance. Beta-lactams achieve bone:serum ratios of 10–30%, requiring high parenteral doses.

Urinary Tract and Renal Parenchyma

• Renal Clearance vs Metabolism: Ciprofloxacin (40–50% unchanged renal clearance) and levofloxacin (>70–80% unchanged renal clearance) achieve massive urinary concentrations exceeding serum levels by 10- to 50-fold, making them potent agents for pyelonephritis and complicated UTI.
• The Moxifloxacin Exception: Moxifloxacin undergoes hepatic glucuronidation and sulfation, with <15–20% excreted unchanged in the urine. Moxifloxacin fails to achieve therapeutic urinary concentrations and is completely ineffective for urinary tract infections (both cystitis and pyelonephritis).
• Nitrofurantoin: Excreted by glomerular filtration to reach high bladder concentrations (>100 mcg/mL), but achieves negligible concentrations in renal parenchyma and prostate tissue. It requires a CrCl ≥ 30 mL/min for therapeutic urinary delivery and is strictly limited to uncomplicated lower tract cystitis.
• Fosfomycin: Excreted unchanged in urine by glomerular filtration, maintaining concentrations >1000 mcg/mL for 24 to 48 hours following a single 3 g oral dose; effective for uncomplicated lower UTI but inadequate for pyelonephritis.